From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

Table 1 Fecal calprotectin cut off values and performance in different populations

Ref.	Patients and disease (n)	Cut-off	Sensitivity (%)	Specificity (%)
Lin et al[23]	1471 IBD (active vs inactive)	50 μg/g	92	60
		100 μg/g	84	66
		150 μg/g	80	82
Limburg et al[24]	110 patients with chronic diarrhea (prediction of inflammation)	100 μg/g	83	83
Von Roon et al[25]	IBD vs no IBD
	1267	50 μg/g	89	81
	328	100 μg/g	98	91
D’Haens et al[27]	126 IBD (large ulcers)	250 μg/g	60.4	79.5
	87 CD (Endoscopic remission)	250 μg/g	94	62.2
	39 UC (Active mucosal disease)
		250 μg/g	71	100
Sipponen et al[29]	77 CD (active vs inactive)	50 μg/g	91	44
		100 μg/g	81	69
		200 μg/g	70	92
Kittanakom et al[21]	40 inactive pediatric CD (prediction of relapse)	400 μg/g	100	75.9
		(PhiCal Calprotectin - EIA)
		500 μg/g (Buhlmann POCT)
		800 μg/g	100	75.9
		(EliA-Calprotectin)
			100	75.9
Vazquez Moron et al[31]	71 CD (active vs inactive)	170 μg/g	77.6	95.5

IBD: Inflammatory bowel diseases; UC: Ulcerative colitis; CD: Crohn’s disease.